drugset / Trial / NCT02708966

Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.

NCT02708966 ↗

Phase 2 Completed 30 enrolled University of Guadalajara
RandomizedParallel-groupDouble-blindTreatment

Summary

Prediabetes (PD) was defined as an state in which glucose levels are above normal but not enough to meet criteria for the diagnosis of type 2 diabetes (T2D). PD can be presented as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and glycated hemoglobin A1c (A1C) altered. The International Diabetes Federation (IDF) reported that in 2013 the prevalence of IGT was 6.9% which is equivalent to approximately 316 million individuals with IGT, it is expected that by 2035 this number will increase to 417 million people affected. Many hypoglycemic effects attributed to Gymnema sylvestre have been reported, including: increase of insulin secretion, regeneration of pancreatic islet cells, increased glucose utilization in various ways and inhibition of glucose uptake in the intestine.

Timeline

Start
2016-03
Primary completion
2018-09
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Gymnema Sylvestre Traditional medicine (herbal / TCM) 300 mg —

Indications